SCHEMBL1632093

SCHEMBL1632093

CS(=O)(=O)c1cccc(-c2cccc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc23)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 5/20 0.56
IKBKB O14920 4/20 0.49
MAPK10 P53779 1/20 0.48
JAK2 O60674 2/20 0.48
BRD4 O60885 1/20 0.48
JAK3 P52333 1/20 0.48
PIK3CD O00329 1/20 0.46
AURKA O14965 1/20 0.46
DCLK1 O15075 1/20 0.46
PIK3C2G O75747 1/20 0.46
PIK3CG P48736 1/20 0.46
MAPK7 Q13164 1/20 0.46
LRRK2 Q5S007 1/20 0.46
AURKB Q96GD4 1/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
DKK1 O94907 1/20 0.46
GSK3B P49841 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632977 0.93 IKBKB (0.53) PTK2IKBKBMAPK10JAK2BRD4
SCHEMBL1633028 0.88 PTK2 (0.57) PTK2IKBKBMAPK10JAK2BRD4
SCHEMBL12724196 0.87 IKBKB (0.51) IKBKBMAPK10JAK2BRD4PIK3CD
SCHEMBL1631112 0.87 IKBKB (0.59) IKBKBMAPK10PIK3CDAURKADCLK1
SCHEMBL29205090 0.84 MAPK10 (0.59) PTK2MAPK10JAK2BRD4JAK3
SCHEMBL1632911 0.84 EGFR (0.55) PTK2IKBKBMAPK10JAK2BRD4
SCHEMBL1632468 0.84 MEN1 (0.55) IKBKBMAPK10JAK2PIK3CDAURKA
SCHEMBL1633411 0.83 MTOR (0.50) IKBKBMAPK10JAK2BRD4CA12
SCHEMBL1632940 0.83 PTK2 (0.56) PTK2IKBKBMAPK10DKK1GSK3B
SCHEMBL1632522 0.83 DKK1 (0.51) IKBKBMAPK10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 PTK2 560/4885IKBKB 980/4885MAPK10 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.